🩺 Navigating the complexities of Non-Muscle Invasive Bladder Cancer (#NMIBC) treatment options brings many uncertainties and challenges, particularly when it comes to recurrence. We sincerely thank the Bladder Cancer Advocacy Network (#BCAN) for raising awareness about CG Oncology's Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. Learn more about our investigational, intravesically delivered oncolytic immunotherapy candidate for BCG-unresponsive NMIBC in this Urology Times article: https://bit.ly/3Ruv3Vq 🎗 Healthcare providers and bladder cancer patients can learn more about CG Oncology’s EAP and its eligibility criteria by visiting www.clinicaltrials.gov (NCT06443944) or emailing EAP@cgoncology.com. #ClinicalTrials #UroOncology #Immunotherapy #PatientCare #DrugDevelopment #Immunotherapy #Therapeutics #CGOncology #cretostimogene
In the Urology Times: An expanded access program (EAP) for cretostimogene grenadenorepvec has been initiated for adult patients in the US with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) who meet certain program eligibility criteria, CG Oncology, the developer of the therapy, announced in a news release. EAPs grant availability to investigational therapeutics for patients outside of clinical trials for whom there is no comparable or satisfactory alternative options. Click here to learn more: https://lnkd.in/gQYSphpz
